GRCL - AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth

2024-02-04 09:21:56 ET

Summary

• AstraZeneca is one of the fastest-growing pharmaceutical companies.
• On February 8, 2024, the company will publish financial results for the 4th quarter of 2023.
• From a broader perspective, AstraZeneca's EPS is expected to continue to grow through 2026.
• Sales of most of AstraZeneca's cancer blockbusters have continued to grow at a rapid pace in recent years.
• So, sales of Imfinzi were $1.13 billion in the third quarter of 2023, up 52.8% year-over-year.

AstraZeneca ( AZN ) is one of the fast-growing pharmaceutical companies that has played a significant role in saving the lives of COVID-19 patients and is known worldwide for innovative medicines such as Lynparza, Farxiga, and Imfinzi.

Thesis

Ahead of AstraZeneca's fourth-quarter 2023 financial results next week , its share price continues to fluctuate near an uptrend line, the first sign that traders and investors remain optimistic regarding its business development in 2024....

For further details see: